期刊
JOURNAL FOR IMMUNOTHERAPY OF CANCER
卷 9, 期 11, 页码 -出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/jitc-2021-003323
关键词
biostatistics; clinical trials as topic; immunotherapy
资金
- NHLBI NIH HHS [R01 HL089778] Funding Source: Medline
In a comparative oncology study, stratified analyses based on patients' baseline characteristics may not be valid or interpretable, especially in immunotherapy studies. This article presents alternative approaches using data from KEYNOTE-189 trial to address the limitations of conventional stratified analyses.
In a comparative oncology study with progression-free or overall survival as the endpoint, the primary or key secondary analysis is routinely stratified by patients' baseline characteristics when evaluating the treatment difference. The validity of a conventional strategy such as a stratified HR analysis depends on stringent model assumptions that are unlikely to be met in practice, especially in immunotherapy studies. Thus, the resulting summary is generally neither valid nor interpretable. This article discusses issues with conventional stratified analyses and presents alternatives using data from KEYNOTE-189, a recent immunotherapy trial for treating patients with metastatic, non-squamous, non-small-cell lung cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据